NCT01502423View on ClinicalTrials.gov

A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

Adalimumab

Subcutaneously 40 mg every other week (eow) or every week (ew) (as dosing requires)

Trial Locations (7)

3145

Site Reference ID/Investigator# 63354, Malvern East

4558

Site Reference ID/Investigator# 63355, Maroochydore

6008

Site Reference ID/Investigator# 63353, Shenton Park

24351

Site Reference ID/Investigator# 69242, Ostseebad Damp

80336

Site Reference ID/Investigator# 63356, Munich

L8N 2B6

Site Reference ID/Investigator# 67105, Hamilton

R3A 1M3

Site Reference ID/Investigator# 64122, Winnipeg

All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01502423 - A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab | Biotech Hunter | Biotech Hunter